Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

German study condemns improper use of anti-decubitus mattresses:

This article was originally published in Clinica

Executive Summary

The improper use of anti-decubitus mattresses in is actually contributing the rise in decubitus incidence in Germany, says Ute Pilzecker, director of the medical care insurance division of the sickness funds' medical service in Schleswig Holstein. An examination of 554 care homes in Schleswig-Holstein last year revealed that the likelihood of patients getting decubitus ulcers addressed was high in only half of those surveyed. Staff were simply not aware of how to treat these ulcers and in only 20% of cases were sufficient measures taken to prevent them. In one particular case a patient weighing 35 kilos was placed on an anti-decubitus alternating system pressure mattress adjusted to accommodate 80 kilos. The hardness of the mattress thus caused the decubitus ulcer.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT066523

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel